Log in
NYSE:TFX

Teleflex Competitors

$373.14
+2.53 (+0.68 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$367.03
Now: $373.14
$376.02
50-Day Range
$318.23
MA: $354.16
$375.50
52-Week Range
$221.27
Now: $373.14
$409.27
Volume361,374 shs
Average Volume254,033 shs
Market Capitalization$17.38 billion
P/E Ratio36.73
Dividend Yield0.37%
Beta1.03

Competitors

Teleflex (NYSE:TFX) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying TFX stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Teleflex, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Teleflex (NYSE:TFX) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Dividends

Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.4%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.3%. Teleflex pays out 12.2% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Teleflex has raised its dividend for 1 consecutive years and Abbott Laboratories has raised its dividend for 48 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

91.3% of Teleflex shares are held by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are held by institutional investors. 2.2% of Teleflex shares are held by insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Teleflex and Abbott Laboratories, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teleflex01913.00
Abbott Laboratories141302.67

Teleflex currently has a consensus target price of $384.6364, suggesting a potential upside of 3.08%. Abbott Laboratories has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Given Abbott Laboratories' higher possible upside, analysts plainly believe Abbott Laboratories is more favorable than Teleflex.

Profitability

This table compares Teleflex and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teleflex18.99%17.15%7.91%
Abbott Laboratories10.50%18.19%8.29%

Volatility and Risk

Teleflex has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Valuation & Earnings

This table compares Teleflex and Abbott Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teleflex$2.60 billion6.70$461.47 million$11.1533.47
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73

Abbott Laboratories has higher revenue and earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Teleflex (NYSE:TFX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Risk & Volatility

Teleflex has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Insider and Institutional Ownership

91.3% of Teleflex shares are owned by institutional investors. Comparatively, 79.9% of Medtronic shares are owned by institutional investors. 2.2% of Teleflex shares are owned by company insiders. Comparatively, 0.5% of Medtronic shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Teleflex and Medtronic's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teleflex$2.60 billion6.70$461.47 million$11.1533.47
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18

Medtronic has higher revenue and earnings than Teleflex. Medtronic is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Dividends

Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.4%. Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.1%. Teleflex pays out 12.2% of its earnings in the form of a dividend. Medtronic pays out 50.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Teleflex has increased its dividend for 1 consecutive years and Medtronic has increased its dividend for 43 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Teleflex and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teleflex18.99%17.15%7.91%
Medtronic15.80%10.47%5.80%

Analyst Recommendations

This is a summary of current ratings for Teleflex and Medtronic, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teleflex01913.00
Medtronic132012.84

Teleflex currently has a consensus target price of $384.6364, suggesting a potential upside of 3.08%. Medtronic has a consensus target price of $118.1538, suggesting a potential upside of 6.47%. Given Medtronic's higher possible upside, analysts clearly believe Medtronic is more favorable than Teleflex.

Summary

Teleflex beats Medtronic on 11 of the 17 factors compared between the two stocks.

Stryker (NYSE:SYK) and Teleflex (NYSE:TFX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Risk & Volatility

Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, Teleflex has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and target prices for Stryker and Teleflex, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
Teleflex01913.00

Stryker currently has a consensus price target of $221.44, suggesting a potential downside of 4.97%. Teleflex has a consensus price target of $384.6364, suggesting a potential upside of 3.08%. Given Teleflex's stronger consensus rating and higher probable upside, analysts plainly believe Teleflex is more favorable than Stryker.

Dividends

Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.0%. Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.4%. Stryker pays out 27.8% of its earnings in the form of a dividend. Teleflex pays out 12.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Stryker has raised its dividend for 1 consecutive years and Teleflex has raised its dividend for 1 consecutive years.

Earnings & Valuation

This table compares Stryker and Teleflex's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.88$2.08 billion$8.2628.21
Teleflex$2.60 billion6.70$461.47 million$11.1533.47

Stryker has higher revenue and earnings than Teleflex. Stryker is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 91.3% of Teleflex shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 2.2% of Teleflex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Stryker and Teleflex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
Teleflex18.99%17.15%7.91%

Teleflex (NYSE:TFX) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk & Volatility

Teleflex has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Teleflex and Intuitive Surgical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teleflex01913.00
Intuitive Surgical371202.41

Teleflex presently has a consensus price target of $384.6364, suggesting a potential upside of 3.08%. Intuitive Surgical has a consensus price target of $718.2778, suggesting a potential downside of 0.11%. Given Teleflex's stronger consensus rating and higher probable upside, analysts plainly believe Teleflex is more favorable than Intuitive Surgical.

Valuation and Earnings

This table compares Teleflex and Intuitive Surgical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teleflex$2.60 billion6.70$461.47 million$11.1533.47
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27

Intuitive Surgical has higher revenue and earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

91.3% of Teleflex shares are owned by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are owned by institutional investors. 2.2% of Teleflex shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Teleflex and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teleflex18.99%17.15%7.91%
Intuitive Surgical24.45%12.08%10.44%

Summary

Teleflex beats Intuitive Surgical on 8 of the 15 factors compared between the two stocks.

Teleflex (NYSE:TFX) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Volatility & Risk

Teleflex has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Teleflex and Becton, Dickinson and, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teleflex01913.00
Becton, Dickinson and07712.60

Teleflex presently has a consensus price target of $384.6364, suggesting a potential upside of 3.08%. Becton, Dickinson and has a consensus price target of $280.2857, suggesting a potential upside of 22.67%. Given Becton, Dickinson and's higher probable upside, analysts plainly believe Becton, Dickinson and is more favorable than Teleflex.

Dividends

Teleflex pays an annual dividend of $1.36 per share and has a dividend yield of 0.4%. Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.4%. Teleflex pays out 12.2% of its earnings in the form of a dividend. Becton, Dickinson and pays out 31.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Teleflex has increased its dividend for 1 consecutive years and Becton, Dickinson and has increased its dividend for 49 consecutive years. Becton, Dickinson and is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Valuation and Earnings

This table compares Teleflex and Becton, Dickinson and's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teleflex$2.60 billion6.70$461.47 million$11.1533.47
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Becton, Dickinson and has higher revenue and earnings than Teleflex. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Teleflex, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

91.3% of Teleflex shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 2.2% of Teleflex shares are owned by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Teleflex and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teleflex18.99%17.15%7.91%
Becton, Dickinson and5.11%13.30%5.60%

Summary

Teleflex beats Becton, Dickinson and on 11 of the 17 factors compared between the two stocks.

Teleflex (NYSE:TFX) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk & Volatility

Teleflex has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Teleflex and Edwards Lifesciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Teleflex01913.00
Edwards Lifesciences251302.55

Teleflex presently has a consensus price target of $384.6364, suggesting a potential upside of 3.08%. Edwards Lifesciences has a consensus price target of $87.7222, suggesting a potential upside of 3.57%. Given Edwards Lifesciences' higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Teleflex.

Valuation and Earnings

This table compares Teleflex and Edwards Lifesciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teleflex$2.60 billion6.70$461.47 million$11.1533.47
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54

Edwards Lifesciences has higher revenue and earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

91.3% of Teleflex shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 2.2% of Teleflex shares are owned by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Teleflex and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Teleflex18.99%17.15%7.91%
Edwards Lifesciences18.18%29.00%18.10%

Summary

Edwards Lifesciences beats Teleflex on 8 of the 15 factors compared between the two stocks.


Teleflex Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27+1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97+0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01+0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05+1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48+1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70+0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33+1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79+1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77+1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09+1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57+0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89+0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07+1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
STERIS logo
STE
STERIS
1.9$189.09+3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50+0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50+1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55+0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Globus Medical logo
GMED
Globus Medical
1.5$58.47+1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78+0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32+2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37+2.1%$2.35 billion$1.26 billion32.44
AtriCure logo
ATRC
AtriCure
1.5$43.24+1.8%$1.95 billion$230.81 million-37.60
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90+1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87+4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14+2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12+2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98+1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94+1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.